Comparison of clinical outcomes among users of oral and transdermal estrogen therapy in the Women's Health Initiative Observational Study
Conclusions: The summary index of risks versus benefits was similar for oral CEE versus oral or transdermal E2-containing regimens. CEE + P containing less than 0.625 mg/d of CEE (vs 0.625 mg/d) for less than 5 years appeared safer.
Source: Menopause - Category: OBGYN Tags: Original Articles Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cardiology | Colorectal Cancer | Coronary Heart Disease | Endometrial Cancer | Estradiol | Heart | Heart Disease | Hysterectomy | Men | Menopause | OBGYN | Oral Cancer | Orthopaedics | Pulmonary Thromboembolism | Stroke | Study | Women